Stillfront - Growth uncertainty remains
Redeye updates estimates and valuation on Stillfront following the company’s Q3-results which came in stronger than we expected. While the company benefits from a strong USD, the uncertainty over organic growth remains as the full year growth guidance was lowered. Still, we have slightly lifted our topline estimates on the back of the positive FX although EBITDA estimates remains largely unchanged. We also lower our valuation range due to an increased discount rate following higher risk-free rate assumptions.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.